B+
Bull case
25%
Probability
Target price
$1.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
BEAT
HeartBeamANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.20
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-11
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+100.0
Score
AI commentary
Recent coverage is constructive around FDA engagement, clinical enrollment, early shipments and lower cash burn, but it is sparse and largely derived from third-party earnings summaries. Reliable post-print analyst revisions, social sentiment, options skew, short interest and employee-review evidence are unavailable. Treat the positive directional prior as monitoring context rather than confirmation of commercial traction.
RankAlpha Sentiment Codex - 2026-09-11
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-31eventALIGN-ACS results at TCT 2026High impact
HeartBeam expects to present full ALIGN-ACS pilot results at TCT 2026 after completing enrollment of 134 patients; the data are intended to inform a U.S. pivotal study and potential indication expansion. Clinical utility and regulatory implications remain unproven [#IR-2026-08-13].
2026-12-31eventFDA feedback on heart-attack detection pathwayHigh impact
Stored Q2 earnings coverage reports that HeartBeam submitted an FDA pre-submission proposing a 510(k) pathway and anticipated feedback within 75 days, potentially clarifying pivotal-trial design and whether a study can begin by year-end 2026 [#PR-EARNINGS-2026-08-14].
2026-12-31catalystATM financing and dilution riskHigh impact
An August 2026 SEC filing describes potential at-the-market sales through ordinary broker transactions. With operations still loss-making, issuance could pressure the share price and dilute existing holders [#8-K-2026-08-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-11 • Updated nightlySource: Internal modelMethodology